The relationship of depression and diabetes: Pathophysiological and treatment implications

Psychoneuroendocrinology

Volumn 36, Issue 9, 2011, Pages 1276-1286

  Rustad, James K ^a   Musselman, Dominique L ^a   Nemeroff, Charles B ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Complications; Depression; Diabetes; Diagnosis; Epidemiology; Glycemic control; Mortality; Pathophysiology; Treatment

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOLAMINE; FLUOXETINE; GLUCAGON; GLUCOCORTICOID; GROWTH HORMONE; HEMOGLOBIN A1C; INSULIN; INSULIN SENSITIZING AGENT; NEUROLEPTIC AGENT; NORTRIPTYLINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADJUVANT THERAPY; CARDIOVASCULAR DISEASE; COGNITIVE THERAPY; COMORBIDITY; DEPRESSION; DIABETES EDUCATION; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FUNCTIONAL DISEASE; GLYCEMIC CONTROL; HIPPOCAMPUS; HUMAN; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; MAJOR DEPRESSION; MENTAL STRESS; MORTALITY; NERVOUS SYSTEM DEVELOPMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOPHYSIOLOGY; PREVALENCE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; REMISSION; REVIEW; RISK FACTOR; SELF CARE; SIDE EFFECT; WEIGHT GAIN;

ANIMALS; BLOOD GLUCOSE; DEPRESSION; DIABETES COMPLICATIONS; DIABETES MELLITUS; DISEASE PROGRESSION; HUMANS;

EID: 80052703370     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2011.03.005     Document Type: Review

References (51)

1. Aikens J.E., Perkins D.W., Piette J.D., Lipton B. Association between depression and concurrent type 2 diabetes outcomes varies by diabetes regimen. Diabetic Med. 2008, 25:1324-1329.
2. Ali S., Stone A., Peters J.L., Davies M.J., Khunti K. The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabetic Med. 2006, 23:1165-1173.
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the study of Obesity Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004, 27:596-601.
4. American Diabetes Association Economic costs of diabetes in the U.S. in 2007. Diabetes Care 2008, 31:596-615.
5. American Diabetes Association Standards of medical care in diabetes - 2010. Diabetes Care 2010, 33(Suppl. 1):S11-S61.
6. Andersohn F., Schade R., Suissa S., Garbe E. Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus. Am. J. Psychiatry 2009, 166:591-598.
7. Anderson R.J., Freedland K.E., Clouse R.E., Lustman P.J. The prevalence of co-morbid depression in adults with diabetes: a meta-analysis. Diabetes Care 2001, 24:1069-1078.
8. Barnard K.D., Skinner T.C., Peveler R. The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabetic Med. 2006, 23:445-448.
9. Butters M.A., Aizenstein H.J., Hayashi K.M., Meltzer C.C., Seaman J., Reynolds C.F., Toga A.W., Thompson P.M., Becker J.T. Three-dimensional surface mapping of the caudate-nucleus in late-life depression. Am. J. Geriatr. Psychiatry 2009, 17:4-12. IMAGe Research Group.
10. Campayo A., de Jonge P., Roy J.F., Saz P., de la Camara C., Quintanilla M.A., Marcos G., Santabarbara J., Lobo A. Depressive disorder and incident diabetes mellitus: the effect of characteristics of depression. Am. J. Psychiatry 2010, 167:580-588.
11. de Groot M., Anderson R., Freedman K.E., Clouse R.E., Lustman P.J. Association of depression and diabetes complications: a meta-analysis. Psychosom. Med. 2001, 63:619-630.
12. Egede L.E. Diabetes major depression, and functional disability among U.S. adults. Diabetes Care 2004, 27:421-427.
13. Egede L.E., Nietert P.J., Zheng D. Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 2005, 28:1339-1345.
14. Fisher E.S. Building a medical neighborhood for the medical home. N. Engl. J. Med. 2008, 359:1202-1205.
15. Gilbody S., Bower P., Fletcher J., Richards D., Sutton A.J. Collaborative care for depression: a cumulative meta-analysis and review of longer-term outcomes. Arch. Intern. Med. 2006, 166:2314-2321.
16. Gill J.M., Klinkman M.S., Chen Y.X. Antidepressant medication use for primary care patients with and without medical co-morbidities: a national electronic health record (EHR) network study. J. Am. Board Fam. Med. 2010, 23:499-508.
17. Golden S.H., Mariana L., Carnethon M., Bertoni A.G., Schreiner P.J., Diez Roux A.V., Lee H.B., Lyketsos C. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008, 299:2751-2759.
18. Gonzalez J.S., Peyrot M., McCarl L.A., Collins E.M., Serpa L., Mimiaga M.J., Safren S.A. Depression and Diabetes Treatment Nonadherence: A Meta-Analysis. Diabetes Care 2008, 31:2398-2403.
19. Gonzalez J.S., Safren S.A., Cagliero E., Wexler D.J., Delahanty L., Wittenberg E., Blais M.A., Meigs J.B., Grant R.W. Depression. Self-Care, and Medication Adherence in Type 2 Diabetes: Relationships across the full range of symptom severity. Diabetes Care 2007, 30:2222-2227.
20. Guo Y., Musselman D.L., Manatunga A.K., Gilles N., Lawson K.C., Porter M.R., McDaniel J.S., Nemeroff C.B. The diagnosis of major depression in patients with cancer: a comparative approach. Psychosomatics 2006, 47:376-384.
21. Katon W.J., Lin E.H.B., Russo J., Von Korff M., Ciechanowski P., Simon G., Ludman E., Bush T., Young B. Cardiac risk factors in patients with diabetes mellitus and major depression. J. Gen. Intern. Med. 2004, 19:1192-1199.
22. Katon W.J., Von Korff M.V., Lin E.H.B., Simon G., Ludman E., Russo J., Ciechanowski P., Walker E., Bush T. The pathways study: a randomized trial of collaborative care in patients with diabetes and depression. Arch. Gen. Psychiatry 2004, 61:1042-1049.
23. Katon W.J., Rutter C., Simon G., Lin E.H.B., Ludman E., Ciechanowski P., Kinder L., Young B., Von Korff M. The association of comorbid depression with mortality in patients with type 2 diabetes. Diabetes Care 2005, 28:2668-2672.
24. Katon W.J., Russo J., Lin E.H.B., Heckbert S.R., Ciechanowski P., Ludman E., Von Korff M.V. Depression and diabetes: factors associated with major depression at five-year follow-up. Psychosomatics 2009, 50:570-579.
25. Krabbe K.S., Nielsen A.R., Krogh-Madsen R., Plomgard P., Rasmussen P., Erikstrup C., Fischer C.P., Lindegaard B., Petersen A.M.W., Taudorf S., Secher N.H., Pilegaard H., Bruunsgaard H., Pedersen B.K. Brain-derived neurotrophic factor (BDNF) and type 2 diabetes. Diabetologia 2007, 50:431-438.
26. Kumar A., Gupta R., Thomas A., Ajilore O., Helleman G. Focal subcortical biophysical abnormalities in patients diagnosed with type 2 diabetes and depression. Arch. Gen. Psychiatry 2009, 66:324-330.
27. Levin A. Collaborative-care model built on " Medical Home" foundation. Psychiatr. News 2009, 44:12.
28. Li C., Ford E.D., Strine T.W., Mokdad A.H. Prevalence of depression among U.S adults with diabetes: findings from the 2006 behavioral risk factor surveillance system. Diabetes Care 2008, 31:105-108.
29. Lustman P.J., Freedland K.E., Carney R.M., Hong B.A., Clouse R.E. Similarity of depression in diabetic and psychiatric patients. Psychosom. Med. 1992, 54:602-611.
30. Lustman P.J., Griffith L.S., Clouse R.E., Freedland K.E., Eisen S.A., Rubin E.H., Carney R.M., McGill J.B. Effects of nortriptyline on depression and glycemic control in diabetes: results of a double-blind placebo-controlled trial. Psychosom. Med. 1997, 59:241-250.
31. Lustman P.J., Griffith L.S., Freedland K.E., Kissel S.S., Clouse R.E. Cognitive behavior therapy for depression in type ii diabetes mellitus: a randomized controlled trial. Ann. Intern. Med. 1998, 129:613-621.
32. Lustman P.J., Anderson R.J., Freedland K.E., De Groot M., Carney R.M., Clouse R.E. Depression and poor glycemic control. Diabetes Care 2000, 23:934-942.
33. Lustman P.J., Freedland K.E., Griffith L.S., Clouse R.E. Fluoxetine for depression in diabetes: a randomized double-blind placebo-controlled trial. Diabetes Care 2000, 23:618-623.
34. Lustman P.J., Clouse R.E., Nix B.D., Freedland K.E., Rubin E.H., McGill J.B., Williams M.M., Gelenberg A.J., Ciechanowski P.S., Hirsch I.B. Sertraline for prevention of depression recurrence in diabetes mellitus: a randomized, double-blind placebo-controlled trial. Arch. Gen. Psychiatry 2006, 63:521-529.
35. McDaniel J.S., Musselman D.L., Porter M.R., Reed D.A., Nemeroff C.B. Depression in patients with cancer: diagnosis biology, and treatment. Arch. Gen. Psychiatry 1995, 55:89-99.
36. McIntyre R.S., Soczynska J.K., Lewis G.F., MacQueen G.M., Konarski J.Z., Kennedy S.H. Managing psychiatric disorders with antidiabetic agents: translational research and treatment opportunities. Exp. Opin. Pharmacother. 2006, 7:1305-1321.
37. McIntyre R.S., Soczynska J.K., Konarski J.Z., Woldeyohannes H.O., Law C.W.Y., Miranda A., Fulgosis D., Kennedy S.H. Should depressive syndromes be reclassified as " Metabolic Syndrome Type II" ?. Ann. Clin. Psychiatry 2007, 19:257-264.
38. Mezuk B., Eaton W.W., Albrecht M.P.H., Golden S.H. Depression and type II diabetes over the lifespan: a meta-analysis. Diabetes Care 2008, 31:2383-2390.
39. Musselman D.L., Evans D.L., Nemeroff C.B. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment, 1998. Arch. Gen. Psychiatry 1998, 55:580-592.
40. Musselman D.L., Betan E., Larsen H., Phillips L.S. Relationship of depression to diabetes types 1 and 2: epidemiology biology, and treatment. Biol. Psychiatry 2003, 54:317-329.
41. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials. Am. J. Psychiatry 2009, 166:980-991.
42. Nichols G.A., Brown J.B. Unadjusted and adjusted prevalence of diagnosed depression in type 2 diabetes. Diabetes Care 2003, 26:744-749.
43. Rhee M.K., Musselman D.L., Ziemer D.C., Vaccarino V., Kolm P., Weintraub W.S., Caudle J.M., Varughese R.M., Irving J.M., Phillips L.S. Unrecognized glucose intolerance is not associated with depression screening for impaired glucose tolerance study 3 SIGT 3. Diabetic Med. 2008, 25:1361-1365.
44. Roose S.P., Glassman A., Mathew S.J., Musselman D.L., Nelson J.C., Steffens D.C. Academic highlights: managing patients with vascular disease and depression. J. Clin. Psychiatry 2006, 67:1633-1644.
45. Rubin R.R., Gaussoin S.A., Peyrot M., DiLillo V., Miller K., Wadden T.A., West D.S., Wing R.R., Knowler W.C. Look AHEAD Research Group. Cardiovascular disease risk factors, depression symptoms and antidepressant medicine use in the Look AHEAD (Action for Health in Diabetes) clinical trial of weight loss in diabetes. Diabetologia 2010, 53:1581-1589.
46. Sheehan D.V., Lecrubier Y., Sheehan K.H., Amorim P., Janavs J., Weiller E., Hergueta T., Baker R., Dunbar G.C. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J. Clin. Psychiatry 1998, 59(Suppl. 20):20-33.
47. Smith T.E., Sederer L.I. A new kind of homelessness for individuals with serious mental illness? the need for a " Mental Health Home" Psychiatr. Serv. 2009, 60:528-533.
48. Sultan S, Luminet O., Hartemann A. Cognitive and anxiety symptoms in screening for clinical depression in diabetes: a systematic examination of diagnostic performances of the HADS and BDI-SF. J. Affect. Disorders 2010, 123:332-336.
49. Wang S., Sun Z., Guo Y., Yuan Y., Yang B. Diabetes impairs hippocampal function via advanced glycation end product mediated new neuron generation in animals with diabetes-related depression. Toxicol. Sci. 2009, 111:72-79.
50. Wild S., Roglic G., Green A., Sicree R., King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004, 27:1047-1053.
51. Winokur A., Maislin G., Phillips J.L., Amsterdam J.D. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am. J. Psychiatry 1988, 145:325-330.